Immune system (under background HBV reverse transcriptase suppression by nucleoside analogs)

The immune system under background HBV reverse transcriptase suppression describes the clinical and biological state of patients with chronic hepatitis B (CHB) who are treated with nucleoside or nucleotide analogs (NAs). NAs like entecavir and tenofovir target the viral reverse transcriptase to stop DNA replication, effectively reducing viral load to undetectable levels in most patients (Marcellin et al., 2013). Despite this suppression, the virus persists in the liver as cccDNA, and the immune system remains in a state of "exhaustion" due to the continuous production of viral proteins like HBsAg (Boni et al., 2007). This specific context is the focus of intense research into "functional cures," where the goal is to use the NA-induced low-viremia state as a window to introduce immunomodulators that can permanently restore the host's antiviral control (Cornberg et al., 2020). Understanding the interplay between viral suppression and immune exhaustion is critical for developing combination therapies that aim for HBsAg loss.

Other names

HBV-suppressed immune environmentImmune restoration in chronic hepatitis BHost immune response under NA therapyImmune system in NA-treated CHB patients

Nucleoside analogs (NAs) competitively inhibit the Hepatitis B virus (HBV) reverse transcriptase (P protein), leading to premature chain termination of viral DNA synthesis and profound suppression of viremia (Marcellin et al., 2013). This suppression is intended to reduce the chronic inflammatory stimulus and alleviate T-cell exhaustion, providing a stable immunological baseline for adjunctive immunotherapies aimed at achieving a functional cure (Boni et al., 2007).